Coherus Oncology, Inc. 8-K

What Happened
On May 11, 2026, Coherus Oncology, Inc. (CHRS) filed a Form 8-K under Item 2.02 to report its financial results for the quarter ended March 31, 2026. The company issued a press release with those results, which is furnished as Exhibit 99.1 to the Form 8-K. The filing was signed by CEO Dennis M. Lanfear.

Key Details

• Press release date: May 11, 2026.
• Reporting period: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K also includes an Inline XBRL cover page (Exhibit 104) and is signed by CEO Dennis M. Lanfear.

Why It Matters
This 8-K notifies investors that Coherus has released its latest quarterly earnings and financial information. Investors should read the Exhibit 99.1 press release for specifics on revenue, earnings, cash position, guidance, or operational updates, since the 8-K itself furnishes (but does not reproduce) those details. Routine procedural filing, but the underlying quarterly results can affect the stock depending on how they compare to expectations.